Prospect: information for the user
Plegridy 63 micrograms injectable solution in pre-filled syringe
Plegridy 94 micrograms injectable solution in pre-filled syringe
Plegridy 125 micrograms injectable solution in pre-filled syringe
peginterferón beta-1a
Read this prospect carefully before starting to use this medication, as it contains important information for you.
What is Plegridy
The active ingredient in Plegridy is peginterferon beta-1a. Peginterferon beta-1a is a long-acting modified form of interferon. Interferons are naturally produced substances in the body that help protect against infections and diseases.
What is Plegridy used for
This medication is used to treat Relapsing-Remitting Multiple Sclerosis (RRMS) in adults 18 years of age or older.
Multiple Sclerosis (MS) is a long-term disease that affects the central nervous system (CNS), including the brain and spinal cord, in which the body's immune system (natural defenses) damages the protective covering (myelin) that surrounds the nerves of the brain and spinal cord. This alters the messages between the brain and other parts of the body, causing MS symptoms.
Patients with RRMS have periods in which the disease is not active (remission) between exacerbations of symptoms (relapses).
Each patient has specific MS symptoms.They may include:
How does Plegridy work?
Plegridy appears to work by preventing the immune system from damaging the brain and spinal cord.This may help reduce the number of relapses you have and slow the disabling effects of MS. Treatment with Plegridy may help prevent worsening, although it will not cure MS.
Do not use Plegridy
Warnings and precautions
Consult your doctor if you have ever had:
Consult your doctor, pharmacist, or nursebefore injecting Plegridyif you have any of the following conditions,as they may worsen while using Plegridy:
(injection site necrosis). When you are ready to administer it, carefully follow the instructions described in section 7 “Instructions for injecting the pre-filled syringe of Plegridy”, at the end of this leaflet. This reduces the risk of injection site reactions;
Other things to consider when using Plegridy
If you accidentally prick or prick another person with the Plegridy needle, wash the affected area with water and soapimmediatelyandcontact a doctor ornurseas soon as possible.
Children and adolescents
Plegridyshould not be usedin children and adolescents under 18 years of age. The safety and efficacy of Plegridy in this age group are unknown.
Plegridy should be used with caution when administered with other medicines that are processed in the body by a group of proteins called “cytochrome P450” (e.g., some medicines used to treat epilepsy or depression).
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medicine, especially those used to treat epilepsy or depression. This includes any medicine obtained without a prescription.
At times, you may need to remind other healthcare professionals that you are being treated with Plegridy, for example, if they prescribe other medicines or perform a blood test. Plegridy may interact with other medicines or the test results.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.
No harmful effects are expected in the infant. Plegridy can be used during breastfeeding.
Driving and operating machinery
The influence of Plegridy on the ability to drive and operate machinery is negligible or insignificant.Plegridy contains sodium
This medicine contains less than 1 mmol of sodium (23 mg); it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Usual Dose
One injection of Plegridy 125 micrograms every 14 days (every two weeks). Try to use Plegridy at the same time on the same day each time you inject.
Plegridy Start
If you are using Plegridy for the first time, your doctor may advise you to start gradually increasing the dose so that you can get used to the effects of Plegridy before administering the full dose. You will be provided with a starter pack that contains the first two injections: a yellow syringe with Plegridy 63 micrograms (for day 0) and a blue syringe with Plegridy 94 micrograms (for day 14).
After that, you will be provided with a maintenance pack that contains grey syringes with Plegridy 125 micrograms (for day 28 and then every two weeks).
Read the instructions in the section 7 “Instructions for Pre-Filled Syringe Injection of Plegridy” at the end of this leaflet before starting to use Plegridy.
Use the printed record box on the inside of the lid of the starter pack to keep a record of the injection dates.
Self-Administration
Plegridy is injected under the skin (subcutaneous injection). Alternate the injection site. Do not use the same injection site for other injections.
You can inject Plegridy without the help of your doctor if you have been taught how to do it.
Duration of Plegridy Treatment
Your doctor will inform you for how long you should use Plegridy. It is essential that you use Plegridy regularly. Do not make any changes that your doctor has not advised.
If you use more Plegridy than you should
You should only inject Plegridy once every two weeks.
If you forget to use Plegridy
You should inject Plegridy once every two weeks. This regular regimen helps to administer the treatment as uniformly as possible.
If you forget to administer it on your usual day, inject a dose as soon as possible and continue as usual. However, do not inject more than once in a period of 7 days. Do not administer two injections to compensate for the missed dose.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects
(frequent: may affect up to 1 in 10 people)
If you experience any of the following symptoms:
(frequent: may affect up to 1 in 10 people)
If you experience:
(rare: may affect up to 1 in 100 people)
If you experience any of the following:
(rare: may affect up to 1 in 100 people)
If you experience a seizure or an epileptic attack.
(rare: may affect up to 1 in 1,000 people)
If you experience any of the following symptoms:
(rare: may affect up to 1 in 1,000 people)
If you experience any of the following symptoms:
(rare: may affect up to 1 in 1,000 people)
The following may occur: blood clots in small blood vessels that may affect your kidneys (thrombotic thrombocytopenic purpura or hemolytic uremic syndrome). Symptoms may include an increase in bruises, bleeding, fever, extreme weakness, headache, dizziness, or fainting. Your doctor may find changes in your blood and kidney function.
If you experience any of the following symptoms:
Other side effects
Very frequent side effects
(may affect more than 1 in 10 people)
Flu-like symptoms
Flu-like symptoms are more common when you first start using Plegridy. As you continue to use the injections, the symptoms will gradually disappear. See below for some simple ways to help reduce the impact of flu-like symptoms if you experience them.
Three simple ways to help reduce the impact of flu-like symptoms:
Frequent side effects
(may affect up to 1 in 10 people)
Rare side effects
(may affect up to 1 in 100 people)
Unknown frequency
(cannot be estimated from available data)
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through thenational notification system included in Appendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
In order to improve the traceability of this medicine, your doctor or pharmacist must register the name and batch number of the medicine that has been administered to you in your medical history. You may also want to note this information for future reference.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label and the box after CAD/EXP. The expiration date is the last day of the month indicated.
Composition of Plegridy
The active ingredient is peginterferon beta-1a.
Each pre-filled syringe of 63 micrograms contains 63 micrograms of peginterferon beta-1a in 0.5 mL of injectable solution.
Each pre-filled syringe of 94 micrograms contains 94 micrograms of peginterferon beta-1a in 0.5 mL of injectable solution.
Each pre-filled syringe of 125 micrograms contains 125 micrograms of peginterferon beta-1a in 0.5 mL of injectable solution.
The other components are sodium acetate trihydrate, glacial acetic acid, arginine hydrochloride, polisorbate 20, and water for injectable preparations (see section 2 “Plegridy contains sodium”).
Appearance of the product and contents of the pack
Plegridy is a transparent and colourless injectable solution in a pre-filled syringe with a attached needle.
Pack sizes:
Only some pack sizes may be marketed.
Marketing Authorisation Holder
Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
Netherlands
FUJIFILM Diosynth Biotechnologies Denmark ApS
Biotek Allé 1
DK-3400 Hillerød
Denmark
Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
Netherlands
Further information on this medicinal product can be obtained by contacting the local representative of the marketing authorisation holder:
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
| ||
|
Last update of this leaflet:01/2025.
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Read the instructions before starting to use Plegridy and each time you receive a new prescription. There may be new information. This information does not replace the conversation with your doctor or nurse about your disease or your treatment.
Nota:
Do not share the pre-filled syringe of Plegridy with anyone else to avoid the transmissionof infections.
Do not use more than one pre-filled syringe every 14 days (every 2 weeks).
Do not use the pre-filled syringe if it has fallen or shows visible damage.
Calendar of administration
The starter pack contains your first two injections to gradually adjust your dose. Choose the correct syringe from the pack.
When | What dose | What pack |
Day 0 (63 micrograms) | First injection: 63 micrograms choose the orange syringe | |
Day 14 (94 micrograms) | Second injection: 94 micrograms choose the blue syringe | |
Day 28 and every 2 weeks thereafter (125 micrograms) | Full dose injection: 125 micrograms choose the grey syringe |
Do not usemore than one pre-filled syringe in a period of 14 days (every 2 weeks).
Materials needed for the injection of Plegridy
Pre-filled syringe of Plegridy (see Figure A)
Before use – Parts of the pre-filled syringe of Plegridy (Figure A)
Additional materials not included in the pack (see Figure B):
Ask your doctor, pharmacist, or nurse for instructions on how to dispose of the used syringes.
Preparation for injection
Step 1: Remove the pre-filled syringe from the refrigerator
Do not use external heat sources, such as hot water, to warm the pre-filled syringeof Plegridy.
Step 2: Gather materials and wash hands
Step 3: Check the pre-filled syringe of Plegridy | |
Do not use the pre-filled syringe of Plegridy once the expiration date has passed.
Do not use the pre-filled syringe of Plegridy if the liquid has a colour, is cloudy, or contains particles in suspension. You may see air bubbles in the Plegridy medication. This is normal and does not need to be removed before injection. |
Administration of the injection
Step 4: Choose and clean the injection site | |
Do not inject directly into the navel. Do not inject into an area of the body that has irritated, painful, red, swollen, bruised, tattooed, infected, or scarred skin.
Do not touch or blow on this area before administering the injection. | |
Step 5: Remove the needle cap firmly | |
Be carefulwhen removing the needle cap to avoid sticking yourself with the needle. Do not touch the needle. Warning: do notput the needle cap back on the pre-filled syringe of Plegridy. You could stick yourself with the needle. |
Step 6: Gently pinch the injection site | |
| |
Step 7: Inject the medication | |
Do not pull the plunger back. | |
Do not remove the syringe from the injection site until the plunger has been pushed down to the bottom. | |
|
Step 8: Remove the syringe from the injection site | |
Warning: do notput the needle cap back on the pre-filled syringe of Plegridy. You could stick yourself with the needle. Do not use the pre-filled syringe again. |
Step 9: Disposal of the used pre-filled syringe of Plegridy
Step 10: Care of the injection site
Step 11: Check the injection site
Record the date and location
General warnings
Do not reuse the pre-filled syringe of Plegridy.
Do not share the pre-filled syringe of Plegridy.
Storage
Do not freeze or expose to high temperatures.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.